Literature DB >> 8822946

Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines.

P Georgii-Hemming1, H J Wiklund, O Ljunggren, K Nilsson.   

Abstract

Human multiple myeloma (MM) represents a highly aneuploid tumor as shown by cytogenetic studies. This may partly explain the heterogeneity with regard to growth factor requirements demonstrated among MM cells. We have previously reported the expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) mRNA in some MM cell lines. In this study we investigated the role of IGF-I as a growth and/or survival factor in three MM cell lines: LP-1, EJM, and Karpas 707. We report that all cell lines expressed IGF-I and IGF-IR mRNA and protein. LP-1 and Karpas 707, but not EJM, were stimulated to proliferation in a dose-dependent manner by exogenous IGF-I. An IGF-IR blocking antibody inhibited both the IGF-I-induced and spontaneous growth of LP-1, and Karpas 707, while the EJM cell line was unaffected by the addition of the antibody. In conclusion, our results show that IGF-I can act as a growth factor in human MM, and they suggest that an autocrine IGF-I loop may contribute to the growth and survival in some MM cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822946

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

2.  Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Authors:  K Mahtouk; F W Cremer; T Rème; M Jourdan; M Baudard; J Moreaux; G Requirand; G Fiol; J De Vos; M Moos; P Quittet; H Goldschmidt; J-F Rossi; D Hose; B Klein
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

3.  Diet-induced obesity promotes a myeloma-like condition in vivo.

Authors:  S T Lwin; S W Z Olechnowicz; J A Fowler; C M Edwards
Journal:  Leukemia       Date:  2014-10-07       Impact factor: 11.528

4.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

Review 5.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

6.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

7.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

8.  Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Authors:  Lei Shi; Siqing Wang; Maurizio Zangari; Hongwei Xu; Thai M Cao; Chunjiao Xu; Yong Wu; Fang Xiao; Yinghong Liu; Ye Yang; Mohamed Salama; Guiyuan Li; Guido Tricot; Fenghuang Zhan
Journal:  Oncotarget       Date:  2010-05

9.  Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.

Authors:  DeannaLee M Beauvais; Oisun Jung; Yang Yang; Ralph D Sanderson; Alan C Rapraeger
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

Review 10.  Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.

Authors:  Karène Mahtouk; Dirk Hose; John De Vos; Jérôme Moreaux; Michel Jourdan; Jean François Rossi; Thierry Rème; Harmut Goldschmidt; Bernard Klein
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.